169 related articles for article (PubMed ID: 38764482)
1. International time trends and differences in topical actinic keratosis therapy utilization.
Zhao HJ; Ushcatz I; Tadrous M; Aoki V; Chang AY; Levell NJ; Von Schuckmann L; Drucker AM
JAAD Int; 2024 Sep; 16():18-25. PubMed ID: 38764482
[TBL] [Abstract][Full Text] [Related]
2. Ingenol Mebutate Is Associated With Increased Reporting Odds for Squamous Cell Carcinoma in Actinic Keratosis Patients, a Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS).
Jedlowski PM
J Cutan Med Surg; 2023; 27(1):39-43. PubMed ID: 36495205
[TBL] [Abstract][Full Text] [Related]
3. A trial-based cost-effectiveness analysis of topical 5-fluorouracil vs. imiquimod vs. ingenol mebutate vs. methyl aminolaevulinate conventional photodynamic therapy for the treatment of actinic keratosis in the head and neck area performed in the Netherlands.
Jansen MHE; Kessels JPHM; Merks I; Nelemans PJ; Kelleners-Smeets NWJ; Mosterd K; Essers BAB
Br J Dermatol; 2020 Oct; 183(4):738-744. PubMed ID: 31961446
[TBL] [Abstract][Full Text] [Related]
4. Topical treatment of actinic keratoses in organ transplant recipients: a feasibility study for SPOT (Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments).
Hasan ZU; Ahmed I; Matin RN; Homer V; Lear JT; Ismail F; Whitmarsh T; Green AC; Thomson J; Milligan A; Hogan S; Van-de-Velde V; Mitchell-Worsford L; Kentley J; Gaunt C; Jefferson-Hulme Y; Bowden SJ; Gaunt P; Wheatley K; Proby CM; Harwood CA
Br J Dermatol; 2022 Sep; 187(3):324-337. PubMed ID: 34988975
[TBL] [Abstract][Full Text] [Related]
5. Interventions for actinic keratoses.
Gupta AK; Paquet M; Villanueva E; Brintnell W
Cochrane Database Syst Rev; 2012 Dec; 12(12):CD004415. PubMed ID: 23235610
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and pharmacodynamic evaluation of ingenol mebutate for the treatment of actinic keratosis.
Stockfleth E; Bastian M
Expert Opin Drug Metab Toxicol; 2018 Sep; 14(9):911-918. PubMed ID: 30074409
[TBL] [Abstract][Full Text] [Related]
7. A cost-utility analysis of ingenol mebutate gel for the treatment of actinic keratosis: a Scottish perspective.
Tolley K; Kemmett D; Thybo S; Nasr R; Smethurst H
Eur J Health Econ; 2016 Apr; 17(3):287-304. PubMed ID: 25795391
[TBL] [Abstract][Full Text] [Related]
8. Ingenol mebutate: A novel topical drug for actinic keratosis.
Aditya S; Gupta S
Indian Dermatol Online J; 2013 Jul; 4(3):246-9. PubMed ID: 23984250
[TBL] [Abstract][Full Text] [Related]
9. Pharmacoeconomic evaluations in the treatment of actinic keratoses.
Tolley K; Argenziano G; Calzavara-Pinton PG; Larsson T; Ryttig L
Int J Immunopathol Pharmacol; 2017 Jun; 30(2):178-181. PubMed ID: 28580871
[TBL] [Abstract][Full Text] [Related]
10. Ingenol mebutate treatment in actinic keratosis - clinical effectiveness and potential side effects.
Lesiak A; Maćkowska A; Bednarski IA; Kolano P; Olejniczak-Staruch I; Woźniacka A; Sieniawska J; Narbutt J
Postepy Dermatol Alergol; 2019 Aug; 36(4):468-471. PubMed ID: 31616223
[TBL] [Abstract][Full Text] [Related]
11. Topical corticosteroid has no influence on inflammation or efficacy after ingenol mebutate treatment of grade I to III actinic keratoses (AK): A randomized clinical trial.
Erlendsson AM; Karmisholt KE; Haak CS; Stender IM; Haedersdal M
J Am Acad Dermatol; 2016 Apr; 74(4):709-15. PubMed ID: 26810403
[TBL] [Abstract][Full Text] [Related]
12. Survey of Patient Satisfaction With Ingenol Mebutate Gel Treatment for Actinic Keratosis From a Community Dermatology Practice.
Schaefer D
Skinmed; 2016; 14(4):259-265. PubMed ID: 27784514
[TBL] [Abstract][Full Text] [Related]
13. Attitudes among dermatologists regarding actinic keratosis treatment options.
Moretta G; Samela T; Sampogna F; Ricci F; Carlesimo F; Panebianco A; D'Erme AM; Di Lella G; Pallotta S; Dellambra E; Abeni D; Fania L
Dermatol Reports; 2022 Sep; 14(3):9392. PubMed ID: 36267162
[TBL] [Abstract][Full Text] [Related]
14. The paradigm shift in treating actinic keratosis: a comprehensive strategy.
Stockfleth E
J Drugs Dermatol; 2012 Dec; 11(12):1462-7. PubMed ID: 23377517
[TBL] [Abstract][Full Text] [Related]
15. Topical Ingenol Mebutate: A New Treatment Modality for Multiple Actinic Keratoses and Field Cancerization.
Kostovic K; Gulin SJ; Mokos ZB; Ceovic R
Anticancer Agents Med Chem; 2017; 17(10):1304-1311. PubMed ID: 28270072
[TBL] [Abstract][Full Text] [Related]
16. Quality of life and side effects in patients with actinic keratosis treated with ingenol mebutate: a pilot study.
Jubert-Esteve E; Del Pozo-Hernando LJ; Izquierdo-Herce N; Bauzá-Alonso A; Martín-Santiago A; Jones-Caballero M
Actas Dermosifiliogr; 2015 Oct; 106(8):644-50. PubMed ID: 26130156
[TBL] [Abstract][Full Text] [Related]
17. Guidelines of care for the management of actinic keratosis: Executive summary.
Eisen DB; Asgari MM; Bennett DD; Connolly SM; Dellavalle RP; Freeman EE; Goldenberg G; Leffell DJ; Peschin S; Sligh JE; Wu PA; Frazer-Green L; Malik S; Schlesinger TE
J Am Acad Dermatol; 2021 Oct; 85(4):945-955. PubMed ID: 34111497
[TBL] [Abstract][Full Text] [Related]
18. Efficacy, safety and tolerability of field treatment of actinic keratosis with ingenol mebutate 0.015 % gel: a single center case series.
Bobyr I; Campanati A; Consales V; Giuliodori K; Scalise A; Offidani A
Springerplus; 2016; 5():627. PubMed ID: 27330893
[TBL] [Abstract][Full Text] [Related]
19. Willingness-to-pay to access Ingenol Mebutate Gel for Actinic Keratosis Treatment in the U.S. Setting.
Willis M; Erntoft S; Persson S; Norlin JM; Persson U
J Health Econ Outcomes Res; 2014; 2(1):1-14. PubMed ID: 34430663
[No Abstract] [Full Text] [Related]
20. Clinical Response to Ingenol Mebutate in Patients With Actinic Keratoses.
Batalla A; Flórez Á; Feal C; Peón G; Abalde MT; Salgado-Boquete L; de la Torre C
Actas Dermosifiliogr; 2015 Dec; 106(10):e55-61. PubMed ID: 26055975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
